

SUPPLEMENTARY TABLE

Supplementary Table S1: Systemic Treatment

Treatment	<i>N</i> = 208	%
Surgery		
Yes	179	86
No (unresectable)	29	14
Surgical procedure (<i>n</i> = 179)		
Major liver surgery	102	57
Minor liver surgery	77	43
Synchron metastases (<i>n</i> = 118)		
Chemotherapy		
5-FU mono	29	25
5-FU + oxaliplatin	61	52
5-FU + irinotecan	15	13
No chemotherapy	13	11
Second-line chemotherapy		
5-FU mono	3	3
5-FU + oxaliplatin	11	9
5-FU + irinotecan	27	23
No second-line chemotherapy	77	65
Metachronous metastases (<i>n</i> = 90)		
Chemotherapy		
5-FU mono	11	12
5-FU + oxaliplatin	25	28
5-FU + irinotecan	15	17
No chemotherapy	39	43
Second-line chemotherapy		
5-FU mono	0	-
5-FU + oxaliplatin	8	9
5-FU + irinotecan	6	7
No second-line chemotherapy	76	84
Biological agents		
Cetuximab	25	12
Bevacizumab	24	12
Cetuximab + bevacizumab	6	3
Cetuximab + bevacizumab + panitumumab	1	0.05
None	152	73